Home > Insider Trading > Filing (0000950170-24-096496)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1832168	Longboard Pharmaceuticals Inc.	LBPH	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1350416	Randall Kaye	4275 Executive Square Suite 950 La Jolla CA 92037	Cmo	No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2024-01-23	100	$24.82	100	No	4	P	Indirect	By Spouse
Common Stock	Disposition	2024-06-25	100	$20.87	0	No	4	S	Indirect	By Spouse
Common Stock	Acquisiton	2024-08-12	16,667	$4.35	34,587	No	4	M	Direct
Common Stock	Disposition	2024-08-12	10,476	$34.55	24,111	No	4	S	Direct
Common Stock	Disposition	2024-08-12	6,191	$35.03	17,920	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	By Spouse
No	4	S	Indirect	By Spouse
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2024-08-12	16,667	$0.00	16,667	$4.35

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
129,633		2033-02-08	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	17,920	Direct

Footnotes

The amount represents restricted stock units that were granted on February 8, 2024, and reported in a Form 4 filed on February 9, 2024. The restricted stock units will vest in four equal annual installments commencing on February 8, 2025, and the shares underlying the restricted stock units will be issued upon vesting and release of the restricted stock units.
The transaction reported in this line item of this Form 4 was effected pursuant to a Rule 10b5-1 trading plan established by the reporting person.
The amount includes the 17,920 restricted stock units described in footnote 1 of this Form 4.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.88 to $34.87, inclusive. The reporting person undertakes to provide Longboard Pharmaceuticals, Inc., any security holder of Longboard Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 4 and 5 to this Form 4.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.88 to $35.32, inclusive.
The shares subject to the stock option vest and become exercisable in 48 equal monthly installments commencing March 9, 2023.